Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-09-04FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved Actavis's supplemental application for buprenorphine and naloxone, a generic opioid dependence treatment.
-
FDA approval · 2013-09-04FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
The FDA approved a supplemental application for buprenorphine hydrochloride submitted by PAI Holdings (dba Pharmaceutical Associates, Inc. a…
-
FDA approval · 2013-09-04FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) submitted by Orexo US, Inc.
-
FDA approval · 2013-09-04FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for buprenorphine, a generic opioid medication. This approval covers …
-
CLINICAL_TRIALS trial_result · 2013-08-23Clinical Trial Update: Aprepitant Effects on Oxycodone Response [NA]
Clinical trial examining how the NK1 receptor antagonist aprepitant affects oxycodone response in individuals with opioid use disorder. The …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-08-08FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
The FDA approved a supplemental application for SUBOXONE (buprenorphine hydrochloride/naloxone hydrochloride) submitted by Indivior Inc.
-
FDA label_change · 2013-07-29FDA Approved: VIVITROL — Supplemental Application (Alkermes, Inc.)
The FDA approved a supplemental application for VIVITROL (naltrexone) from Alkermes, Inc., resulting in changes to the product label.
-
CLINICAL_TRIALS trial_result · 2013-07-22Clinical Trial Update: The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
A completed clinical trial examining the prevalence of HIV drug resistance and the risk of HIV transmission among people receiving opioid ag…
-
CLINICAL_TRIALS withdrawal · 2013-07-22Clinical Trial Update: Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol). [NA]
A clinical trial evaluating a primary care model for treating opioid use disorder with the long-acting injectable naltrexone (Vivitrol) has …
-
FDA approval · 2013-07-03FDA Approved: ZUBSOLV — Original Application (Orexo US, Inc.)
FDA approved ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) from Orexo US, Inc. under its Original Application (NDA204242)…
-
FDA approval · 2013-06-26FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for methadone hydrochloride from Mylan Institutional LLC, resulting in updated labeling/manufact…
-
CLINICAL_TRIALS research · 2013-06-20Clinical Trial Update: Study of Opioid Immunosuppressive Effects
This document provides an update on a clinical trial investigating the immunosuppressive effects of opioids. The trial status is currently u…
-
CLINICAL_TRIALS research · 2013-06-11Clinical Trial Update: Trial of Methadone Maintenance Versus Methadone Detox in Jail [NA]
This clinical trial update describes a study comparing methadone maintenance with methadone detox in incarcerated individuals with opioid us…
-
CLINICAL_TRIALS trial_result · 2013-05-06Clinical Trial Update: Acceptance Therapy During Methadone Detoxification [Phase 1]
Phase 1 clinical trial evaluating Acceptance Therapy during methadone detoxification for opioid use disorder has completed.
-
CLINICAL_TRIALS trial_result · 2013-05-01Clinical Trial Update: Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release [Phase 1, Phase 2]
This clinical trial explored buprenorphine maintenance therapy for individuals with opioid use disorder in jail and after release; the study…
-
FDA approval · 2013-04-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for Methadone Hydrochloride manufactured by VistaPharm, LLC.
-
FDA approval · 2013-04-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for methadone hydrochloride, a generic product manufactured by Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2013-04-15Clinical Trial Update: Effective Treatment for Prescription Opioid Abuse [Phase 2]
Phase 2 clinical trial evaluating a treatment for opioid use disorder has completed. The drug name is not provided in the available informat…
-
FDA approval · 2013-04-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for methadone hydrochloride from SpecGx LLC. This approval pertains to a supplemental change to the …
-
FDA approval · 2013-04-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for methadone hydrochloride (generic methadone) under ANDA, authorizi…
-
CLINICAL_TRIALS trial_result · 2013-03-22Clinical Trial Update: Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse [Phase 1]
A Phase 1 clinical trial evaluated the safety and potential efficacy of cannabidiol as a treatment intervention for opioid relapse. The stud…
-
FDA approval · 2013-02-22FDA Approved: BUPRENORPHINE AND NALOXONE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis's generic buprenorphine and naloxone product under an original ANDA for the treatment of opioid use disorder.
-
FDA approval · 2013-02-22FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Original Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's original application for a generic buprenorphine HCl and naloxone HCl product. This approval p…
-
FDA approval · 2013-02-21FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for buprenorphine from Hikma Pharmaceuticals USA Inc., resulting in modifications to an already appr…
-
CLINICAL_TRIALS trial_result · 2013-02-21Clinical Trial Update: The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1
Completed Johns Hopkins trial comparing methadone and buprenorphine for pregnant women with opioid use disorder, assessing fetal neurobehavi…